NO329605B1 - (Imidazol-1-yl-metyl)pyridazinforbindelser, fremgangsmate for fremstilling av slike, medikament inneholdende slike forbindelser, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer - Google Patents

(Imidazol-1-yl-metyl)pyridazinforbindelser, fremgangsmate for fremstilling av slike, medikament inneholdende slike forbindelser, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer Download PDF

Info

Publication number
NO329605B1
NO329605B1 NO20044666A NO20044666A NO329605B1 NO 329605 B1 NO329605 B1 NO 329605B1 NO 20044666 A NO20044666 A NO 20044666A NO 20044666 A NO20044666 A NO 20044666A NO 329605 B1 NO329605 B1 NO 329605B1
Authority
NO
Norway
Prior art keywords
methyl
pyridazine
methylimidazol
prepared
compound
Prior art date
Application number
NO20044666A
Other languages
English (en)
Norwegian (no)
Other versions
NO20044666L (no
Inventor
Marie-Paule Heitz Neidhart
Bernd Buettelmann
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20044666L publication Critical patent/NO20044666L/no
Publication of NO329605B1 publication Critical patent/NO329605B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20044666A 2002-05-16 2004-10-28 (Imidazol-1-yl-metyl)pyridazinforbindelser, fremgangsmate for fremstilling av slike, medikament inneholdende slike forbindelser, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer NO329605B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16
PCT/EP2003/005151 WO2003097637A1 (en) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker

Publications (2)

Publication Number Publication Date
NO20044666L NO20044666L (no) 2004-12-15
NO329605B1 true NO329605B1 (no) 2010-11-22

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044666A NO329605B1 (no) 2002-05-16 2004-10-28 (Imidazol-1-yl-metyl)pyridazinforbindelser, fremgangsmate for fremstilling av slike, medikament inneholdende slike forbindelser, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer

Country Status (31)

Country Link
US (1) US7005432B2 (ru)
EP (1) EP1506190B1 (ru)
JP (1) JP4267569B2 (ru)
KR (1) KR100632868B1 (ru)
CN (1) CN1312151C (ru)
AR (1) AR040010A1 (ru)
AT (1) ATE329912T1 (ru)
AU (1) AU2003242542B2 (ru)
BR (1) BR0311177A (ru)
CA (1) CA2485926C (ru)
CL (1) CL2004001251A1 (ru)
CY (1) CY1105159T1 (ru)
DE (1) DE60306152T2 (ru)
DK (1) DK1506190T3 (ru)
ES (1) ES2265581T3 (ru)
HK (1) HK1080845A1 (ru)
HR (1) HRP20041060B1 (ru)
IL (1) IL164922A (ru)
MA (1) MA27117A1 (ru)
ME (1) MEP76708A (ru)
MX (1) MXPA04011253A (ru)
NO (1) NO329605B1 (ru)
NZ (1) NZ536310A (ru)
PL (1) PL211340B1 (ru)
PT (1) PT1506190E (ru)
RS (1) RS51200B (ru)
RU (1) RU2317294C2 (ru)
SI (1) SI1506190T1 (ru)
TN (1) TNSN04224A1 (ru)
WO (1) WO2003097637A1 (ru)
ZA (1) ZA200408789B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
WO2006117052A1 (de) * 2005-05-03 2006-11-09 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 1−ブロモ−3−フルオロ−5−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
TWI457333B (zh) 2009-02-05 2014-10-21 Takeda Pharmaceutical 嗒酮化合物
JP5785548B2 (ja) * 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
WO2017140771A1 (en) 2016-02-18 2017-08-24 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
PE20210948A1 (es) 2018-08-03 2021-05-24 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromatico y usos de los mismos
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020293584A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GluN2B receptor modulators
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JOP20210328A1 (ar) 2019-06-14 2023-01-30 Janssen Pharmaceutica Nv مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
WO2020249796A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708171A (pt) 1996-03-08 1999-07-27 Hoffmann La Roche Uso de derivados de 4-fenil-3,6-di-hidro-2h-piridila como bloqueadores de subtipo de receptor nmda
CA2220649C (en) 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
MXPA02010261A (es) 2000-04-20 2003-04-25 Hoffmann La Roche Derivados de pirrolidina y piperidina y su uso para el tratamiento de transtornos neurodegenerativos.
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002028814A2 (en) 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
KR20040106558A (ko) 2004-12-17
IL164922A (en) 2012-01-31
ES2265581T3 (es) 2007-02-16
RS51200B (sr) 2010-12-31
CA2485926C (en) 2009-11-24
RU2004136979A (ru) 2005-07-10
CN1312151C (zh) 2007-04-25
AU2003242542B2 (en) 2008-10-16
MEP76708A (en) 2011-12-20
CN1653062A (zh) 2005-08-10
DE60306152T2 (de) 2007-04-26
HRP20041060A2 (en) 2005-06-30
JP2005532326A (ja) 2005-10-27
ATE329912T1 (de) 2006-07-15
SI1506190T1 (sl) 2006-10-31
CA2485926A1 (en) 2003-11-27
IL164922A0 (en) 2005-12-18
RU2317294C2 (ru) 2008-02-20
CL2004001251A1 (es) 2005-04-22
MXPA04011253A (es) 2005-01-25
PT1506190E (pt) 2006-11-30
EP1506190B1 (en) 2006-06-14
BR0311177A (pt) 2005-03-15
EP1506190A1 (en) 2005-02-16
PL374224A1 (en) 2005-10-03
RS98504A (en) 2006-12-15
NO20044666L (no) 2004-12-15
NZ536310A (en) 2007-08-31
CY1105159T1 (el) 2009-11-04
DK1506190T3 (da) 2006-10-16
HRP20041060B1 (en) 2012-11-30
ZA200408789B (en) 2005-12-28
DE60306152D1 (de) 2006-07-27
TNSN04224A1 (fr) 2007-03-12
US20030229096A1 (en) 2003-12-11
AU2003242542A1 (en) 2003-12-02
HK1080845A1 (en) 2006-05-04
PL211340B1 (pl) 2012-05-31
WO2003097637A1 (en) 2003-11-27
AR040010A1 (es) 2005-03-09
JP4267569B2 (ja) 2009-05-27
MA27117A1 (fr) 2004-12-20
US7005432B2 (en) 2006-02-28
KR100632868B1 (ko) 2006-10-13

Similar Documents

Publication Publication Date Title
NO329605B1 (no) (Imidazol-1-yl-metyl)pyridazinforbindelser, fremgangsmate for fremstilling av slike, medikament inneholdende slike forbindelser, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer
AU2003302220B2 (en) Tricyclic steroid hormone nuclear receptor modulators
US6380238B1 (en) Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands
JP4612990B2 (ja) ヒスタミン−3受容体リガンドとしての新規アミンおよびそれらの治療的適用
CA2173243A1 (en) Benzothiophenes and related compounds as estrogen agonists
DK158307B (da) Analogifremgangsmaade til fremstilling af 4-(fenylalkyl)-imidazolderivater eller farmaceutisk acceptable syreadditionssalte deraf
RU2382766C2 (ru) Производные арилсульфонилстильбена для лечения бессонницы и связанных с ней расстройств
NO170277B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocyklus-substituerte toluennitriler
WO2007044796A2 (en) Pyridazinone compounds as calcilytics
DK158351B (da) Analogifremgangsmaade til fremstilling af substituerede 4-fenylalkylimidazolderivater eller farmaceutisk acceptable syreadditionssalte deraf
Wang et al. One-pot synthesis of pyrano [3, 2-c] pyran derivatives catalyzed by KF/Al2O3
CA2485298C (en) Substituted pyrazolyl compounds for the treatment of inflammation
NO176357B (no) Analogifremgangsmåte for fremstilling av 4,5,7,8-tetrahydro-6H-tiazolo [5,4-dÅ- azepiner
US3969415A (en) 1-(2-Naphthyl)-2,3-butadien-1-ols
Rubiralta et al. Synthesis and reactivity of 2-(1', 3'dithian-2'-yl) indoles
JPH07188226A (ja) 2−(1−ピロリジノ)−置換ベンゾオキサゾール類及び該化合物を含有するロイコトリエン生合成阻害剤
US5541217A (en) 4-arylcyclopenta[c]pyrrole analgesics
CA2071398A1 (en) Aminomethyl-substituted 2,3-dihydropyrano/2,3-b/pyridines, process for their preparation and their use in medicaments
WO2008034579A1 (en) 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
HU186656B (en) Process for producing new benzhydryl-piperazine derivatives, acid additionak salts and pharmaceutical compositions containing them
CN116693467A (zh) 一种噻唑胺类mbl抑制剂及其制备方法和用途
Skorcz et al. 2, 1‐benzisothiazoline 2, 2‐dioxide. I. Some 3‐substituted derivatives

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EVOTEC INTERNATIONAL GMBH, DE

MM1K Lapsed by not paying the annual fees